Paper Details

  1. Home
  2. Paper Details

Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain.

Author: CoxStephanie M, DieckmannGabriela, EngertRyan C, HamrahPedram, OzmenM Cuneyt

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This retrospective study aims to assess the efficacy and tolerability of low-dose naltrexone (LDN) in refractory neuropathic corneal pain (NCP) patients.
Paper Details　
Original Abstract of the Article :
Neuropathic corneal pain (NCP) is caused by damage or disease of the somatosensory nervous system that innervates the cornea and presents with symptoms of pain or persistent unpleasant sensations, such as burning, dryness, or light sensitivity. This retrospective study aims to assess the efficacy an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/33450415

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Desert of Pain: Low-Dose Naltrexone for Neuropathic Corneal Pain

Neuropathic corneal pain (NCP) is a debilitating condition that affects the cornea, the clear outer layer of the eye. This study explores the potential of low-dose naltrexone (LDN) as a treatment for refractory NCP, a type of NCP that does not respond to conventional therapies. The researchers conducted a retrospective study to evaluate the efficacy and tolerability of LDN in patients with refractory NCP. The study found that LDN was effective in reducing pain symptoms and well-tolerated by patients, offering a potential new avenue for managing this challenging condition.

A New Oasis in the Desert of Pain: Low-Dose Naltrexone for Neuropathic Corneal Pain

This study suggests that LDN may offer a new hope for individuals suffering from refractory NCP. The researchers' findings provide promising evidence for the effectiveness of LDN in managing pain symptoms, potentially improving quality of life for those struggling with this debilitating condition.

A New Oasis in the Desert of Pain: Low-Dose Naltrexone for Neuropathic Corneal Pain

If you're experiencing NCP, it's essential to consult with an ophthalmologist to explore all available treatment options. LDN may offer a promising new approach for managing refractory NCP, but it's crucial to discuss this option with your healthcare provider to determine if it's the right choice for you.

Dr. Camel's Conclusion

NCP can be a relentless and debilitating condition, creating a desert of pain for those affected. LDN emerges as a potential oasis in this desert, offering hope for relief from this challenging condition. This study highlights the importance of ongoing research to find new ways to manage NCP and improve the lives of those affected.

Date :
  1. Date Completed 2021-07-05
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

33450415

DOI: Digital Object Identifier

NIHMS1789534

Related Literature

Article Analysis
・Side Effects of naltrexone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.